OK thanks, that makes sense. I do not know what specific type of tumor I have; neuroendocrine was not mentioned, but nothing else was either. As you say, the specific type makes a difference in the treatment plan. It's my understanding that that's why they'll test the tissue samples--to see exactly what they are and what they might respond best to. We'll start with the modified Folfirinox until we have those results. The testing will be done by Caris and is called next-generation sequencing. It's supposed to provide detailed molecular profiling including DNA, RNA and proteins to help target the cancer with specific medications.